Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G01 (Qingdao Wanming Bio-Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Qingdao Wanming Cyber Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
G01 is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), developed by Qingdao WanMing BioCell Pharmaceutics. It is uniquely formulated as an ophthalmic solution (eye drops) intended for the treatment of retinal vascular diseases, including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The drug is designed to overcome the limitations of current anti-VEGF therapies, which typically require frequent intravitreal injections, by providing a non-invasive topical delivery route that can effectively reach the posterior segment of the eye. G01 is currently undergoing Phase I clinical evaluation to assess its safety, tolerability, and pharmacokinetics in healthy subjects.
- Other names
- G01 Eye DropsG-01 Eye DropsG 01 Eye DropsG01 Eye Drops MADG-01 Eye Drops MADG 01 Eye Drops MADG01 Eye Drops SADG-01 Eye Drops SADG 01 Eye Drops SAD
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)NGFR (p75NTR)
Beyond the preview
Go deeper on G01 (Qingdao Wanming Bio-Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G01 (Qingdao Wanming Bio-Pharmaceutical).